Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

FCR-I/iven combination for CLL: «Cheap but fierce»

View Full Paper
Ask AI
Bookmark
Share

Authors

VDVitaly S. DubovЕЗЕ. Е. ЗвонковOSOlga Shtetsova

Discussion

Loading...

Member takes

Overview

Randomized trial improved progression-free survival and minimal residual disease clearance in CLL patients, indicating the effectiveness of tailored targeted therapy.

Key Points

  • To evaluate the efficacy and safety of combining FCR with ibrutinib and venetoclax in CLL treatment.
  • Evaluated previously untreated CLL patients
  • Administered 3 to 6 cycles of FCR with or without ibrutinib and venetoclax
  • Assessed minimal residual disease with flow cytometry after treatment
  • 100% overall response rate in patients completing therapy
  • Observed 100% progression-free survival and overall survival rates
  • No significant differences in outcomes based on genetic mutations

Cite This Study

Dubov et al. (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d205https://doi.org/10.1182/blood-2025-7425
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1MRD-guided ibrutinib plus venetoclax improves outcomes in CLL patients with TP53, ATM, or NOTCH1 aberrations compared to ibrutinib and FCR: Results from the Phase III NCRI FLAIR trial2025
  2. 2A fixed-duration, chemo-sparing approach in CLL: 8-year results of the phase 2 icll-07 filo trial2025
  3. 3Time-limited pirtobrutinib, venetoclax, and obinutuzumab combination in first-line chronic lymphocytic leukemia2025 · 3 citations
  4. 4A Phase II trial of obinutuzumab, ibrutinib and venetoclax in patients with previously untreated follicular lymphoma; A University of California hematologic malignancies consortium study2025
  5. 5Mutation-guided finite-duration acalabrutinib plus venetoclax for relapse after first-line finite-duration COVALENT Bruton tyrosine kinase inhibitor plus venetoclax‒based combination therapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: Phase 2 MAVRiC study2025